 TRILOGY 2 study on CaPre did not meet its primary endpoint CaPre was a krill-oil derived prescription drug designed to treat hypertriglyceridemia What Acasti Pharma does: Acasti Pharma Inc NASDAQ:ACST CVE:ACST had been developing a krill-oil derived prescription drug called CaPre to treat hypertriglyceridemia high levels of triglycerides in the blood, which is known to contribute to heart disease. However, in August last year, the company revealed that a TRILOGY 2 study on CaPre had not met its primary endpoint and said it would not file a New Drug Application with the US Food and Drug Administration. 